James Blair
Affiliations: | 2003-2008 | Cellular and Molecular Pharmacology | University of California, San Francisco, San Francisco, CA |
Google:
"James Blair"Parents
Sign in to add mentor| Kevan Michael Shokat | grad student | 2003-2008 | UC Berkeley | |
| (Chemical genetic tools to measure and regulate cellular kinase activity.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Barkovich KJ, Hariono S, Garske AL, et al. (2012) Kinetics of inhibitor cycling underlie therapeutic disparities between EGFR-driven lung and brain cancers. Cancer Discovery. 2: 450-7 |
| Amin DN, Sergina N, Ahuja D, et al. (2010) Resiliency and vulnerability in the HER2-HER3 tumorigenic driver. Science Translational Medicine. 2: 16ra7 |
| Wong CH, Baehner FL, Spassov DS, et al. (2009) Phosphorylation of the SRC epithelial substrate Trask is tightly regulated in normal epithelia but widespread in many human epithelial cancers. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 2311-22 |
| Apsel B, Blair JA, Gonzalez B, et al. (2008) Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nature Chemical Biology. 4: 691-9 |
| Blair JA, Rauh D, Kung C, et al. (2007) Structure-guided development of affinity probes for tyrosine kinases using chemical genetics. Nature Chemical Biology. 3: 229-38 |
| Sergina NV, Rausch M, Wang D, et al. (2007) Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature. 445: 437-41 |